Get the Stockscreener App
0.6771
2.90%
-0.0202
After Hours:
.67
-0.0071
-1.05%
Plus Therapeutics Inc stock is traded at $0.6771, with a volume of 7.54M.
It is down -2.90% in the last 24 hours and up +51.37% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.6973
Open:
$0.7
24h Volume:
7.54M
Relative Volume:
0.35
Market Cap:
$67.21M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.2676
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
-23.88%
1M Performance:
+51.37%
6M Performance:
-9.72%
1Y Performance:
-50.58%
1-Day Range:
$0.6602
$0.71
1-Week Range:
$0.65
$0.859
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.6771 | 69.22M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Order flow analysis tools used on Plus Therapeutics Inc.New Guidance & Accurate Buy Signal Notifications - newser.com
Real time scanner hits for Plus Therapeutics Inc. explainedJuly 2025 Outlook & Weekly High Return Stock Opportunities - newser.com
Plus Therapeutics Inc. stock outlook for YEARJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Why Plus Therapeutics Inc. stock remains on watchlists2025 Earnings Surprises & Stock Portfolio Risk Control - newser.com
What momentum shifts mean for Plus Therapeutics Inc.Dip Buying & Daily Price Action Insights - newser.com
Heatmap analysis for Plus Therapeutics Inc. and competitors2025 Price Action Summary & Step-by-Step Trade Execution Guides - newser.com
Multi factor analysis applied to Plus Therapeutics Inc.IPO Watch & Weekly High Return Stock Opportunities - newser.com
What MACD and RSI say about Plus Therapeutics Inc.Gold Moves & Short-Term Swing Trade Alerts - newser.com
Is Plus Therapeutics Inc. stock entering bullish territoryJuly 2025 Selloffs & Smart Swing Trading Techniques - newser.com
Using Ichimoku Cloud for Plus Therapeutics Inc. technicalsJuly 2025 Price Swings & Reliable Price Breakout Signals - newser.com
Will Plus Therapeutics Inc. stock outperform tech sector in 20252025 Short Interest & Real-Time Chart Pattern Alerts - newser.com
Plus Therapeutics' (PSTV) Sell (E+) Rating Reaffirmed at Weiss Ratings - MarketBeat
Top chart patterns to watch in Plus Therapeutics Inc.July 2025 Volume & AI Driven Stock Reports - newser.com
What machine learning models say about Plus Therapeutics Inc.2025 Momentum Check & AI Enhanced Execution Alerts - newser.com
Can trapped investors hope for a rebound in Plus Therapeutics Inc.Earnings Growth Summary & Accurate Entry/Exit Alerts - newser.com
Using data models to predict Plus Therapeutics Inc. stock movement2025 Market Overview & Low Drawdown Momentum Ideas - newser.com
How Plus Therapeutics Inc. (XMP0) stock compares with tech leadersTrade Analysis Report & Verified Swing Trading Watchlists - newser.com
How to monitor Plus Therapeutics Inc. with trend dashboardsQuarterly Trade Report & Safe Entry Momentum Tips - newser.com
Is Plus Therapeutics Inc a good long term investmentEarnings Season Recap & Small Entry Cost Stocks - earlytimes.in
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Plus Therapeutics (NASDAQ:PSTV) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says - MarketBeat
Ascendiant Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Plus Therapeutics (PSTV) Price Target Raised by Ascendiant Capital | PSTV Stock News - GuruFocus
Identifying reversal signals in Plus Therapeutics Inc.Weekly Trade Review & Free Fast Entry Momentum Trade Alerts - newser.com
Can Plus Therapeutics Inc. (XMP0) stock double in coming yearsFed Meeting & Fast Gain Stock Tips - newser.com
Why Plus Therapeutics Inc. (XMP0) stock attracts HNW investorsEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Using Bollinger Bands to evaluate Plus Therapeutics Inc.Entry Point & Weekly Breakout Opportunity Watchlist - newser.com
Is it too late to sell Plus Therapeutics Inc.Market Activity Recap & Proven Capital Preservation Tips - newser.com
Plus Therapeutics Stock (PSTV) Opinions on UnitedHealthcare Coverage Deal - Quiver Quantitative
How to interpret RSI for Plus Therapeutics Inc. stock2025 Historical Comparison & Risk Adjusted Buy and Sell Alerts - newser.com
Published on: 2025-10-03 00:59:32 - newser.com
What technical patterns form on Plus Therapeutics Inc. (XMP0) stock chartsTrade Risk Report & Safe Entry Trade Signal Reports - newser.com
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Plus Therapeutics Inc Stock (PSTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
38,323 |
0 |
48,138 |
| Lenk Robert P | Director |
Aug 22 '25 |
Buy |
0.49 |
110,000 |
53,779 |
139,327 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):